BSE / NSE Daily Intraday Calls And Stock Tips: Bonus Issues, Stock Splits, Rights Issues, IPO Updates: Buy Recommendation

Sunday, June 20, 2010

Bonus Issues, Stock Splits, Rights Issues, IPO Updates: Buy Recommendation – HDIL

Buy Recommendation – HDIL
Buy Recommendation – Gail India
Buy Recommendation – Pratibha Industries
Buy Recommendation – Aurobindo Pharma

Posted: 20 Jun 2010 12:32 PM PDT

The password to see buy calls is: LIFEISCOLOURFUL The password to see buy calls is: LIFEISCOLOURFUL The renewed fortunes of the Transferable Development Rights (TDR) market, coupled with HDIL’s steady progress in its slum rehabilitation and residential projects add impetus to the company’s earnings prospects. Concerns over a subdued TDR market, high leverage and, more recently, some of the old promoters opting out of [...]

Read More...

Buy Recommendation – Gail India

Posted: 20 Jun 2010 12:21 PM PDT

The password to see buy calls is: LIFEISCOLOURFUL The password to see buy calls is: LIFEISCOLOURFUL Investors with a high-risk appetite can consider buying the stock of GAIL (India), the country’s predominant natural gas transmission and trading player. At its current price of Rs 472, the stock has gained almost 70 per cent over the past year and discounts its trailing [...]

Read More...

Buy Recommendation – Pratibha Industries

Posted: 20 Jun 2010 12:19 PM PDT

The password to see buy calls is: LIFEISCOLOURFUL The password to see buy calls is: LIFEISCOLOURFUL Investors with a penchant for risk and a medium-term perspective can buy the stock of construction and infrastructure company Pratibha Industries. At Rs 380, the stock trades at 11.4 times per share earnings for FY-10. Valuations are at a discount to peers such as MBL Infra. However, [...]

Read More...

Buy Recommendation – Aurobindo Pharma

Posted: 20 Jun 2010 12:17 PM PDT

The password to see buy calls is: LIFEISCOLOURFUL The password to see buy calls is: LIFEISCOLOURFUL Long-term investments can be considered in the stock of Aurobindo Pharma, a leading API (active pharmaceutical ingredient) and formulations manufacturer. Improving financial performance, likely ramp-up in MNC contracts including the long-term supply agreement with Pfizer and a sales mix tilted towards high-margin formulations business, suggest healthy growth potential [...]

Read More...